INVANZ

Dose: 1 g
Single Dose: 1 (1)
Frequency: 24 hourly
Route: IV
Instructions: For Infection Prophylaxis: Prophylaxis of surgical site infection following elective colorectal surgery:Should be given one hour prior to surgical incision

Ertapenem Na is the derivative of Ertapenem. It is of Synthetic origin. . The Molecular Weight of Ertapenem is 497.50. Its pKa is 4.05.

Ertapenem is contraindicated in conditions like Breast feeding.

The severe or irreversible adverse effects of Ertapenem, which give rise to further complications include Blood clot in vein, Collapsed portion of lung, Decrease Neutrophills.The symptomatic adverse reactions produced by Ertapenem are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Anorexia, Diarrhea, Abdominal pain, Dry mouth, Rashes, Pruritus, Dyspepsia, Hypotension, Nausea and vomiting, Antibiotic-associated colitis, Raised platelet count, Injection-site reactions, Dry mouth, dizziness, dyspepsia.

Ertapenem is primarily indicated in conditions like Community acquired pneumonia, Gynaecologic infections, Intra-abdominal infections, Skin infections, Urinary tract infection.

No data regarding the interactions of Ertapenem was found.

Liver Function Test (LFT)

Drug should not be given to patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Ertapenem should be used with extreme caution in renal impairment (avoid if creatinine clearance less than 30ml/min) and in pregnancy (avoid unless potential benefit outweighs risk).